Quack’s ‘Treatment’ Paralyses 68-Year-Old Woman In Telangana

HYDERABAD:  A 68-year-old woman from Tandur was left bedridden, with total loss of sensation in one leg, after receiving ‘treatment’ from a quack two months ago. The case came to light on Friday after the woman’s family got into an altercation with the accused.

On learning of the malpractice, Telangana State Medical Council (TGMC) is taking it up as a suo moto case to file an FIR against the unqualified practitioner, Mukith.Mukith had been under TGMC’s radar and escaped a raid at his clinic a fortnight ago. He managed to flee from his clinic in Daulatabad in Vikarabad, where he had administered three steroid injections to the patient, Lakshmibai, who had sought treatment from him for knee pain.

‘Quack gave woman 3 steroid injections’

The injections Mukith administered led to sepsis of the knee joint, a swollen leg and fever.

Lakshmibai was rushed to another doctor who performed surgery to remove the infected tissue.

Orthopaedic surgeon Dr Santosh Kumar, who is treating Lakshmibai, said: “She was given three steroid injections in the knee joints. These injections are prescribed only for certain conditions… When she came to me, her entire knee joint was damaged due to sepsis. The family also lost all their money in getting treatment from the quack. Although her leg was saved, it is completely unstable and has no sensation…”

Mukith was among the seven unqualified practitioners raided a fortnight ago by TGMC officials. Six FIRs were lodged after the raids in Parigi, Moinabad, and Daulatabad areas. “We had prescriptions of Mukith, but when the raid started in Daulatabad, he got the information through their network. He shut down the clinic and fled,” said TGMC chief Dr G Srinivas.

Related Posts

  • Pharma
  • March 20, 2025
  • 17 views
Patanjali’s study on Renogrit, that fights cancer drug-induced kidney damage, among 2024’s most notable research papers

A research paper published on Patanjali’s Renogrit, a formulation that is effective against cancer drug cisplatin’s damaging effect on kidneys, has been featured among the most notable research studies of 2024.…

  • Pharma
  • March 19, 2025
  • 122 views
Strides Pharma approves demerger from Arco Labs

Strides Pharma is set to demerge from Arco Labs, a global capability centre, the company said in its exchange filing on Wednesday. Board of Directors of Strides Pharma Science Limited (Strides) and Arco…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Patanjali’s study on Renogrit, that fights cancer drug-induced kidney damage, among 2024’s most notable research papers

Patanjali’s study on Renogrit, that fights cancer drug-induced kidney damage, among 2024’s most notable research papers

Strides Pharma approves demerger from Arco Labs

Strides Pharma approves demerger from Arco Labs

Milestone Pharma Expands Sale Agreement, Increases Offering

Milestone Pharma Expands Sale Agreement, Increases Offering

Novo Nordisk regains membership in UK pharma body

Novo Nordisk regains membership in UK pharma body

USV Joins Empagliflozin generic contest, launches its brand Xenia

USV Joins Empagliflozin generic contest, launches its brand Xenia

SMS Hospital revamps blood safety protocols after fatal transfusion error

SMS Hospital revamps blood safety protocols after fatal transfusion error